As the fourth leading cause of cancer death in the United States, pancreatic cancer remains one of the most deadly forms of cancer.
Pancreatic cancer survival rates are poor as more than 90 percent of pancreatic cancer patients die within the first year of diagnosis. Recent advancements have had little impact patients' pancreatic cancer prognosis, and new pancreatic cancer treatments are desperately needed.
Cancer Fundraising That Benefits Pancreatic Cancer Research at Penn Medicine
Founded in 2008, Stand Up To Cancer (SU2C or Stand Up 2 Cancer) has raised more than $180 million for innovative cancer research including pancreatic cancer research. As one of the most recognized cancer foundations, Stand Up 2 Cancer has made grants to seven multi-disciplinary "Dream Teams" of cancer researchers as well as to 26 young innovative scientists who are undertaking potentially high-reward projects to end the reign of cancer as a leading cause of death in the world today.
Led by the work of Jeffrey Drebin, MD, PhD, and through the Abramson Cancer Center, Penn Medicine has been able to translate pancreatic cancer research into major discoveries that have found new treatments for pancreatic cancer.
Penn Medicine's Abramson Cancer Center is one of seven sites coordinating "Dream Teams" and the only site coordinating projects focusing on pancreatic cancer.
These Penn clinicians and researchers are part of the Stand Up 2 Cancer Pancreatic Cancer Dream Team.
Chi Van Dang, MD, PhD
Professor of Medicine, Hematology/Oncology
Director, Abramson Cancer Center
Director, Abramson Family Cancer Research Institute
Jeffrey A. Drebin, MD, PhD, FACS
John Rhea Barton Professor of Surgery
Chairman, Department of Surgery